NeuroSense Therapeutics Ltd. cotiza a 3.48 USD y tiene una capitalización bursátil de $7M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination o…
| Periodo | 2025-04 | 2024-12 | 2024-09 | 2024-06 |
|---|---|---|---|---|
| Real | $-1.20 | $-2.20 | $-0.40 | $-7.00 |
| Estimado | $-3.00 | $-2.20 | $-3.60 | $-4.10 |
| Sorpresa | +60.0% | +0.0% | +88.9% | -70.7% |
| Métrica | NRSN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -1082.2% | -32.0% | -1050.2% |
| Current Ratio | 0.31 | 2.84 | -2.53 |
| Debt / Equity | — | 0.28 | — |